ArticleOncology letters2026
Metachronous primary non-small cell lung cancer and mucinous tubular and spindle cell carcinoma of the left kidney: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple primary malignant tumors (MPMTs) refer to two or more independent malignancies occurring at different anatomical sites. The present study reports the first documented case of metachronous primary lung adenocarcinoma and renal mucinous tubular and spindle cell carcinoma (MTSCC). A 69-year-old man underwent a radical lobectomy for stage IIB (pT2aN1M0) lung adenocarcinoma followed by adjuvant chemotherapy. A routine 10-month postoperative follow-up computed tomography scan revealed an ill-defined left renal mass. Subsequently, a partial nephrectomy was performed. Histopathological examination confirmed MTSCC. No recurrence was observed after 3 years of surveillance. The present study is, to the best of our knowledge, the first to report the association between lung adenocarcinoma and MTSCC, which highlights the necessity to consider a new primary malignancy in cancer survivors with new lesions. The present case highlights the critical role of integrated histopathological and immunohistochemical evaluation in distinguishing rare primary cancers, such as MTSCC, from metastasis, thus guiding appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.